Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
Herthena-Lung02 data are an ASCO shocker.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Starglo isn't applicable to a US population, an adcom rules.
